Biotinylated Human GPRC5D VLP
Catalog No: GPRC5D-HB003
- Species
- Human
- Expression System
- HEK293
- Tag
- Biotin, His
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human GPRC5D VLP is expressed in HEK293 cells. It contains amino acid residues Met1-Val345 (It may have cross reaction with anti-His antibody) (UniProt accession: Q9NZD1-1).
Product Details
- Molecular Aliases
- GPRC5D; MGC129713; MGC129714; orphan G-protein coupled receptor
- Protein Length
- Met1-Val345
- Expression System
- HEK293
- Theoretical Molecular Weight
- The target protein has a predicted MW of 39.6 kDa.
- Purity
- > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22μm filtered solution in PBS, 300mM L-arginine (pH 7.4).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
The purity of Biotinylated Human GPRC5D VLP is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human GPRC5D VLP at 5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-GPRC5D Antibody, hFc Tag with the EC50 of 7.4ng/ml determined by ELISA (QC Test).
Biotinylated Human GPRC5D VLP captured on CM5 Chip via Streptavidin can bind Anti-GPRC5D Antibody with an affinity constant of 0.28 nM as determined in SPR assay (Biacore T200).
Background
G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor that is primarily expressed in plasma cells and hard keratinized tissues, with low expression in normal human tissues. GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma.
References
- Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10. PMID: 36507686.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.